Vaccine countdown update: 10 Nov - positive results from some, cash flow concerns with others
A metal processor covered here would appear to justify a much higher rating, while cash flow concerns continue to cast a shadow over a once popular litigation funder. Read on here for more on these and other stories.
The news that Pfizer and Germany’s BioNTech have made progress with a Covid-19 vaccine saw stock markets soar, although not all stocks rose, with some beneficiaries of the pandemic, notably small UK biotech stocks, falling sharply, as many clearly think their glory days will soon be coming to an end.
Previous article Next article
DON'T MISS OUT!
Get top investment ideas to help safeguard and grow your wealth.
Invaluable insight from the exciting world of smaller companies.
REGISTER FREE
More on James Cropper
Bonkers Bargains: AIM elder delivers ahead
Don’t be fooled by the 175 year history, this elderly business has a reputation for innovation…
The plot thickens | Bonkers Bargain updates
A patent dispute turns murkier, while a lockdown winner is now struggling for survival. Elsewhere, there…
More on Jubilee Metals Group
Strap yourself in for the commodity supercycle
Are we on the verge of a new commodity supercycle, including gold and silver copper and…
Vaccine countdown update: 10 Nov - positive results from some, cash flow concerns with others
A metal processor covered here would appear to justify a much higher rating, while cash flow…
More on Manolete Partners PLC
Naked Wines: stripping shareholders bare
Results and updates covered here include yet more disappointment for shareholders of online wine retailer Naked…
Vaccine countdown update: 12 Nov - apparent value here and probably a few traps
Our coverage here includes several modestly valued companies whose shares should recover strongly when the world…
More on Zoo Digital
Lofty valuations | Stretched balance sheets
Results and updates covered in our free update here include several companies carrying lofty…
Updates covered here include news of more big share purchases from a founder and CEO of…
More Director buying to encourage
More Company Insights
Bonkers Bargains: AIM elder delivers ahead
The plot thickens | Bonkers Bargain updates
Scientific excellence
Another £1 billion company for AIM | Fuel cell potential and more
Strap yourself in for the commodity supercycle
Vaccine countdown update: 10 Nov - positive results from some, cash flow concerns with others
Naked Wines: stripping shareholders bare
Vaccine countdown update: 12 Nov - apparent value here and probably a few traps
Vaccine countdown update: 10 Nov - positive results from some, cash flow concerns with others
Coronavirus impact: 14 July - plenty of updates and a bizarre response from Manolete
Lofty valuations | Stretched balance sheets
More Director buying to encourage
Sensyne gets its dosh | Valuations!
AIM’s global leader and a smaller alternative
More Company Insights
Poor safety controls | Challenge to AIM?
CVS Group: great results but…
Looking good | Hard to Judge | As flat as it gets
